恶性阻塞性黄的最小侵入性治疗的进展
Li-Min Kang1, Lei Xu2, Fa-Kun Yu2
1Department of Hepatobiliary and Pancreatic Surgery, Puer People's Hospital, Puer 665000, Yunnan Province, China. kanglimin2010@163.com.
World journal of gastrointestinal surgery
|December 30, 2024
概括
恶性阻塞性黄 (MOJ) 是由胆道瘤引起的,导致肝脏问题和困难的手术. 最少侵入性治疗,如内镜和皮肤间排水,为管理这种情况提供了替代方案.
科学领域:
- 肝病学和胃肠病学 肝病学和胃肠学
- 在瘤学瘤学.
背景情况:
- 恶性阻塞性黄 (MOJ) 是由于胆道堵塞而引起的,原因是胆管癌和胰腺癌等癌症.
- 胆管阻塞导致胆红素升高,肝功能受损,并限制了手术治疗选择.
研究的目的:
- 审查恶性阻塞性黄的挑战和最少侵入性治疗方式.
- 要突出当前的方法来管理MOJ当手术切除是不可行的.
主要方法:
- 关于恶性阻塞性黄研究的文献综述.
- 对微创胆道排水技术的分析.
主要成果:
- MOJ带来了重大的临床挑战,包括高白血症和肝功能障碍.
- 最少的侵入性选择,如内镜胆道疏通,超声波引导的程序,以及皮间胆道穿孔疏通是有效的缓解.
结论:
- 最少侵入性胆道排水为MOJ患者提供了关键的治疗选择.
- 这些技术提高了生活质量,并在治疗性手术不可能时管理并发症.
关键词:
内镜逆行性胆血管造机图 (cholangiopancreatography) 是一种内镜逆行式胆血管造机图.恶性阻塞性黄.通过皮肤通过肝脏的胆管排水.无线电频率剥离法 无线电频率剥离法超声波内镜检查 超声波内镜检查更多相关视频
11:03Robotic Left Hepatectomy using Indocyanine Green Fluorescence Imaging for an Intrahepatic Complex Biliary Cyst
Published on: June 24, 2022
5.4K
03:33Author Spotlight: Advancing Hepatobiliary and Pancreatic Tumor Treatment with Minimally Invasive Surgical Techniques
Published on: September 27, 2024
695
相关概念视频
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
